Bispecifics, multispecifics and T cell engagers at PEGS Europe 2026

Nov 16–19, 2026 Lisbon, Portugal ~1.5k attendees Website

61 organizations at PEGS Europe 2026 present work in bispecifics, multispecifics and t cell engagers: 37 drug developers, 15 suppliers and service providers and 9 academic, government and non-profit bodies. Between them they bring 130 presentations to the program. Most represented: AstraZeneca (12 on the program), Roche (8 on the program), iBET (7 on the program). As of Oct 8, 2026.

All 541 organizations at PEGS Europe 2026 →

Showing 1–5 of 61 organizations

Organization	PEGS Europe 2026 Attendance
AstraZeneca Cambridge, UK
astrazeneca.com Large pharma Global pharmaceutical company with oncology, immunology, respiratory and rare disease medicines, including antibodies and ADCs.	Talk Tue Nov 17 9:30am–10:00am Building the Protein Lab of the Future at AstraZeneca: Automation First Science and AI Ready Data at Scale Leveraging Data Science for Enhanced Protein Expression Chair Tue Nov 17 11:44am–11:45am Chairperson's Remarks Display of Biologics Chair Tue Nov 17 2:00pm–2:05pm Chairperson's Remarks Display of Biologics Talk Tue Nov 17 5:20pm–5:50pm Machine Learning for Lead Optimisation Workflow (MeLLOw): Integrating in silico and Wet Lab Data for Biologics Engineering Optimisation & Developability Panel Tue Nov 17 5:50pm–6:20pm BEST PRACTICES FOR IN SILICO DESIGN OF ANTIBODIES: What We Know Now Display of Biologics · with Specifica, Merck KGaA, Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) Talk Tue Nov 17 5:50pm–6:20pm Engineering Affinity Attenuated and Effector CD8 Biased T Cell Engagers T Cell Engagers Chair Wed Nov 18 8:25am–8:30am Chairperson’s Remarks Machine Learning for Protein Engineering Part 1 Talk Wed Nov 18 11:15am–11:45am Stability Prediction for Multispecific Antibodies Machine Learning for Protein Engineering Part 1 Talk Wed Nov 18 11:45am–12:15pm Application of Expression Strategies for Integral Membrane Protein Production Designing High-Performance Expression Platforms Chair Thu Nov 19 8:25am–8:30am Chairperson's Remarks Highly Parallel Protein Discovery Workflows Talk Thu Nov 19 8:30am–8:50am Evolutionary Algorithms for Peptide Design and Optimisation Novel Peptide Drug Discovery Talk Thu Nov 19 9:00am–9:30am Next-Generation Protein Characterisation: An Integrated Mass Spectrometry Strategy from Structured Proteins to Intrinsically Disordered Proteins Highly Parallel Protein Discovery Workflows Talk Thu Nov 19 11:15am–11:45am Targeting Peptides for Enhanced Tissue Delivery Novel Peptide Drug Discovery Talk Thu Nov 19 11:45am–12:05pm AI for Biologics: Transition from Discovery to Design Machine Learning for Protein Engineering Part 2 Talk Thu Nov 19 5:15pm–5:45pm Optimal Design of Masks for Protease-Activated Biologics: What Works, What Doesn’t, and Why Next-Generation Immunotherapies
Roche Basel, Switzerland
roche.com Large pharma Swiss pharmaceutical and diagnostics company whose research units discover and develop antibodies, bispecifics and other biologic medicines.	Chair Tue Nov 17 8:25am–8:30am Chairperson's Remarks Optimisation & Developability Talk Tue Nov 17 11:45am–12:15pm Elucidating the Structure-PK Relationship of Complex Antibody Formats and Understanding the Underlying Mechanisms for Improved Drug Design Safety and Efficacy of Bispecific and Multispecific Antibodies Talk Tue Nov 17 2:05pm–2:35pm From Molecules to Drug Readiness Optimisation & Developability Talk Wed Nov 18 9:30am–10:00am Characterisation of a Biparatopic Sweeping Antibody Biologics for Autoimmune Diseases Talk Wed Nov 18 2:35pm–3:05pm Next-Generation T Cell Engagers: Leveraging Protease Activation to Overcome Toxicity and Expand the Therapeutic Window Advancing Multispecific Antibodies and Combination Therapy to the Clinic Talk Wed Nov 18 2:35pm–3:05pm Novel Orthogonal Receptor Platform Activating the IL12 Pathway in CAR-T Cells Using a Small-Molecule Ligand Advances in Immunoengineering Talk Wed Nov 18 6:25pm–6:50pm Robust Production of Virus-Like Particles in HEK293 Cell Lines Designing High-Performance Expression Platforms Talk Thu Nov 19 11:15am–11:45am Next-Generation FVIIIa-Mimetic Bispecific Antibody NXT007 for Hemophilia A: Evaluation in Preclinical Models Engineering the Next Generation of Bispecific Antibodies Talk Thu Nov 19 11:45am–12:15pm Insights into Fab Nebulisation: How to Minimise Aggregates for Inhaled Biologics Protein Stability & Formulation
iBET Oeiras, Portugal	◆Corporate Support Sponsor
ibet.pt AcademicCorporate Support Sponsor Portuguese non-profit research institute doing protein production, antibody discovery and bioprocess work, including contract research for industry.	Booth Exhibiting at Booth 123 Tue, Nov 1710:30am–7:50pmWed, Nov 1810:30am–5:30pmThu, Nov 1910:00am–2:00pm Chair Tue Nov 17 8:25am–8:30am Chairperson's Welcome Remarks Leveraging Data Science for Enhanced Protein Expression Talk Tue Nov 17 5:20pm–5:50pm The Development of iSeRa-AI, a Tool for Automatic Selection of mAbs from Antibody Display Coupled to Deep Sequencing Display of Biologics Talk Tue Nov 17 5:50pm–6:20pm 3D Tumour Microenvironments Enable Mechanistic Profiling of ADCs and Immunomodulatory Antibodies Safety and Efficacy of Bispecific and Multispecific Antibodies Talk Wed Nov 18 11:15am–11:45am Integrating Genome-Wide CRISPR Screening and Host Cell Engineering in HeLaS3 Producer Lines for rAAV Production Designing High-Performance Expression Platforms Talk Wed Nov 18 7:00pm–7:30pm Decoding Macrophage-Fibroblast Cross-Talk to Enable Next-Generation Anti-Fibrotic Therapies Analytical Characterisation of Biotherapeutics Talk Thu Nov 19 8:30am–9:00am Advanced Bioanalytics for Comprehensive Characterisation of Biotherapeutics Manufacturing Highly Parallel Protein Discovery Workflows Panel Thu Nov 19 5:05pm–5:45pm Higher-Throughput Biopharmaceutical Workflow Challenges Highly Parallel Protein Discovery Workflows · with University of Surrey, University College London, Septerna +1 more
Merck KGaA Darmstadt, Germany
merckgroup.com Large pharma German science and technology group whose healthcare business develops antibodies, ADCs and other biologics; it also runs a life science tools business.	Talk Tue Nov 17 3:05pm–3:35pm Integrating AI/ML and Next-Generation Sequencing for Accelerated Discovery of Single Domain Antibodies Display of Biologics Talk Tue Nov 17 4:50pm–5:20pm Digitalizing ADC Discovery: Building an Integrated Data and Workflow Platform Optimisation & Developability Panel Tue Nov 17 5:50pm–6:20pm BEST PRACTICES FOR IN SILICO DESIGN OF ANTIBODIES: What We Know Now Display of Biologics · with AstraZeneca, Specifica, Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) Chair Thu Nov 19 8:25am–8:30am Chairperson's Remarks Engineering the Next Generation of Bispecific Antibodies Chair Thu Nov 19 10:44am–10:45am Chairperson's Remarks Engineering the Next Generation of Bispecific Antibodies Talk Thu Nov 19 10:45am–11:15am Decoding Photodegradation of ADC Payloads: Integrating in silico Modelling with Experimental Evidence to Understand and Predict Stability Protein Stability & Formulation Talk Thu Nov 19 4:45pm–5:15pm Multifunctional Antibody-Derived Receptor Agonists for Targeted Immunomodulation Next-Generation Immunotherapies
Regeneron Tarrytown, NY
regeneron.com Large pharma Biotechnology company with marketed antibody medicines, discovered with its VelocImmune mice, and a pipeline including CD3 bispecifics.	Talk Tue Nov 17 11:15am–11:45am Targeting Alternative T Cell Effector Pathways to Enhance the Anti-Tumour Activity of CD3-Engaging Bispecific Antibodies Safety and Efficacy of Bispecific and Multispecific Antibodies Chair Wed Nov 18 8:25am–8:30am Chairperson's Remarks Advancing Multispecific Antibodies and Combination Therapy to the Clinic Chair Wed Nov 18 2:00pm–2:05pm Chairperson's Remarks Advancing Multispecific Antibodies and Combination Therapy to the Clinic Talk Wed Nov 18 2:35pm–3:05pm A Novel Approach to Enhance Tissue Specific Gene Delivery Biologics for Autoimmune Diseases Talk Wed Nov 18 6:00pm–6:30pm Advancing CD3 Bispecifics for Solid Tumour Indications Engineering Antibodies & Beyond